This is in line with observations from the PPMI cohort, where reduced DAT availability in the caudate nucleus shortly after diagnosis was associated with an elevated risk of clinical progression to cognitive impairment, depression and gait problems in the next four years. This evidence concerns the gene SLC6A3 and depressive symptom measurement.